林清轩获证监会备案 冲刺港股“国货高端护肤第一股”

Core Viewpoint - Lin Qingxuan is advancing its IPO process in Hong Kong, aiming to become the leading domestic high-end skincare brand in the market, leveraging its unique product offerings and competitive advantages in the industry [1][2]. Company Overview - Lin Qingxuan plans to issue up to 16.061 million shares for overseas listing on the Hong Kong Stock Exchange, marking a significant step in its IPO journey [1]. - The company is recognized as the only domestic brand among the top 15 high-end skincare brands in China, including international brands, and holds the leading position in the domestic high-end national skincare market [1]. Financial Performance - From 2022 to 2024, Lin Qingxuan's revenue is projected to grow from 690 million yuan to 1.21 billion yuan, with a compound annual growth rate (CAGR) of 32.3%, significantly outpacing the industry average [2]. - The flagship product, Lin Qingxuan Camellia Oil, has sold over 30 million bottles since its launch in 2014, maintaining its position as the top-selling facial oil in China for 11 consecutive years [2]. Product and R&D - Lin Qingxuan has invested heavily in R&D, with expenses increasing from 21.12 million yuan in 2022 to 30.40 million yuan in 2024, resulting in 80 patents, including 42 related to core ingredients and technologies [2]. - The flagship patented ingredient, Qingxuan Extract, derived from high-altitude red camellia flowers, offers targeted skin benefits such as enhancing elasticity and reducing fine lines [2]. Market Position and Strategy - The company has established a unique competitive advantage through full value chain integration, from raw material procurement to product development and production, ensuring high-quality product offerings [1][2]. - Lin Qingxuan is redefining high-end domestic skincare with its comprehensive control over the supply chain and an omnichannel sales model, positioning itself for continued leadership in the plant-based skincare revolution in China [2].